Galapagos NV (GLPG)
24.00
-0.24 (-0.99%)
At close: Jan 14, 2025, 3:59 PM
23.79
-0.88%
Pre-market Jan 15, 2025, 05:26 AM EST
undefined% (undefined)
| Bid | 23.73 |
| Market Cap | 1.58B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.94 |
| PE Ratio (ttm) | -25.53 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 23.79 |
| Volume | 434,838 |
| Avg. Volume (20D) | 238,677 |
| Open | 24.57 |
| Previous Close | 24.24 |
| Day's Range | 23.82 - 24.59 |
| 52-Week Range | 23.82 - 40.34 |
| Beta | undefined |
About GLPG
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The compan...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 27, 2012
Employees 1,123
Stock Exchange NASDAQ
Ticker Symbol GLPG
Website https://www.glpg.com
Analyst Forecast
According to 4 analyst ratings, the average rating for GLPG stock is "Hold." The 12-month stock price forecast is $30.5, which is an increase of 27.08% from the latest price.
Buy 0.00%
Hold 75.00%
Sell 25.00%
Next Earnings Release
Galapagos NV is scheduled to release its earnings on Feb 12, 2025,
during market hours.
Analysts project revenue of $72.17M, reflecting a -29.35% YoY shrinking and earnings per share of -0.3, making a -111.36% decrease YoY.
Analysts project revenue of $72.17M, reflecting a -29.35% YoY shrinking and earnings per share of -0.3, making a -111.36% decrease YoY.
4 months ago ·
Source
+9.66%
Galapagos shares are trading higher after Ecor1 Ca...
Unlock content with
Pro Subscription
10 months ago ·
Source
-8.28%
Galapagos shares are trading lower following FY23 earnings.
